ROCK2 expression was associated with poor overall survival of MGMTlow (MGMT−) recurrent gliomas with TMZ therapy (n = 100, Fig 1H), compared with MGMThigh (MGMT+) subset (Fig. 1H, I). This evidence concerns the gene MGMT and central nervous system cancer.